What are the main functions and effects of Sotorasibu?

Sotorasib is a targeted therapy drug mainly used to treat patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutations. KRAS gene mutation is a common gene mutation in lung cancer, especially KRAS G12C mutation, which plays an important role in patients with non-small cell lung cancer. As an oral small molecule inhibitor, sotoraxib specifically binds to the mutated form of KRAS G12C protein and inhibits its activity, thereby preventing the proliferation and spread of tumor cells.

The main efficacy of this drug is to significantly reduce the tumor burden and improve clinical efficacy in patients with KRAS G12C mutant lung cancer. Studies have shown that sotorasiib has a good therapeutic effect on patients with advanced non-small cell lung cancer with KRAS G12C mutations, and can significantly extend the progression-free survival (PFS) and improve the overall survival (OS) of patients. In addition, sotoracib can significantly relieve patients' symptoms and help them maintain a higher quality of life.

In addition to non-small cell lung cancer, sotorasiib has shown potential efficacy in studies of other cancer types. Including some solid tumors with KRAS G12C mutations, such as colorectal cancer, pancreatic cancer, etc., sotoracib has also shown certain therapeutic prospects. Although the drug is currently most widely used in non-small cell lung cancer, its efficacy may apply to other tumor types associated with KRAS G12C mutations.
As a targeted drug, sotoracib has shown good results in the treatment of KRAS G12C mutant cancers, but patients may also face some side effects during use. Common side effects include diarrhea, nausea, fatigue, etc. Nonetheless, the side effects of sotoraxib are relatively manageable and can be tolerated by most patients. Therefore, patients need to conduct regular monitoring under the guidance of a doctor when using this drug to ensure efficacy and safety.
Reference: https://www.lumakras.com/